Denali Advisors LLC Makes New $155,000 Investment in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)

Denali Advisors LLC acquired a new position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX) in the 1st quarter, Holdings Channel reports. The institutional investor acquired 47,300 shares of the biotechnology company’s stock, valued at approximately $155,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ALDX. Citigroup Inc. raised its stake in Aldeyra Therapeutics by 34.6% in the 3rd quarter. Citigroup Inc. now owns 113,036 shares of the biotechnology company’s stock worth $755,000 after purchasing an additional 29,031 shares in the last quarter. SG Americas Securities LLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at about $39,000. International Assets Investment Management LLC increased its holdings in Aldeyra Therapeutics by 319.2% in the 4th quarter. International Assets Investment Management LLC now owns 205,335 shares of the biotechnology company’s stock valued at $7,210,000 after buying an additional 156,353 shares during the period. Prime Capital Investment Advisors LLC bought a new position in Aldeyra Therapeutics in the 4th quarter valued at about $35,000. Finally, Strs Ohio increased its holdings in Aldeyra Therapeutics by 270.8% in the 4th quarter. Strs Ohio now owns 87,500 shares of the biotechnology company’s stock valued at $307,000 after buying an additional 63,900 shares during the period. Institutional investors and hedge funds own 59.71% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a report on Monday, May 6th. Oppenheimer reissued an “outperform” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a report on Monday, May 6th. Finally, StockNews.com lowered shares of Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 22nd.

Insider Buying and Selling

In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc bought 37,712 shares of the business’s stock in a transaction that occurred on Friday, April 5th. The shares were acquired at an average cost of $4.74 per share, for a total transaction of $178,754.88. Following the transaction, the insider now directly owns 9,275,851 shares in the company, valued at $43,967,533.74. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 8.50% of the stock is owned by corporate insiders.

Aldeyra Therapeutics Trading Down 1.5 %

Shares of Aldeyra Therapeutics stock traded down $0.05 during midday trading on Wednesday, hitting $3.20. 164,575 shares of the company traded hands, compared to its average volume of 497,284. The firm’s fifty day moving average price is $3.82 and its 200-day moving average price is $3.59. Aldeyra Therapeutics, Inc has a 12 month low of $1.42 and a 12 month high of $8.38.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, May 2nd. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.06). Equities research analysts forecast that Aldeyra Therapeutics, Inc will post -0.23 earnings per share for the current fiscal year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.